Overcoming resistance to platinum therapy in patients with advanced cancer

American Journal of Cancer

Volumn 1, Issue 4, 2002, Pages 247-255

  Kelland, Lloyd R ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; BBR 3464; BMY 45594; CARBOPLATIN; CISPLATIN; DNA; DOXORUBICIN; EPTAPLATIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GLUTATHIONE; GUANINE; LOBAPLATIN; METALLOTHIONEIN; NEDAPLATIN; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; SATRAPLATIN; TAXANE DERIVATIVE; THIOL DERIVATIVE; THIOPLATIN; TOPOTECAN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER RESISTANCE; DIARRHEA; DNA STRAND; DRUG DNA BINDING; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LEUKOPENIA; LIVER TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOLID TUMOR; TESTIS CANCER; THROMBOCYTOPENIA;

EID: 0041883089     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200201040-00002     Document Type: Review

References (58)

1. Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965; 205: 698-9
2. Takahara PM, Rosenzweig AC, Frederick CA, et al. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 1995; 377: 649-52
3. Harrap KR. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 1985; 12 Suppl. A: 21-33
4. Fichtinger-Schepman AJ, van der Veer JL, den Hartog JHJ, et al. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantitation. Biochemistry 1985; 24: 707-13
5. Huang H, Zhu L, Reid BR, et al. Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 1995; 270: 1842-5
6. Kartalou M, Essigmann JM. Recognition of cisplatin adducts by cellular proteins. Mutat Res 2001; 478: 1-21
7. Knox RJ, Friedlos F, Lydall DA, et al. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloro platinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986; 46: 1972-9
8. Ohndorf U-M, Rould MA, He Q, et al. Basis for recognition of cisplatin-modified DNA by high mobility group proteins. Nature 1999; 399: 708-12
9. Johnson SW, Ferry KV, Hamilton TC. Recent insights into platinum drug resistance in cancer. Drug Resist Updat 1998; 1: 243-54
10. Kartalou M, Essigrnann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001; 478: 23-43
11. Sharp SY, Rogers P, Kelland LR. Transport of cisplatin and bis-acetato-ammine dichlorocyclohexylamine platinum(IV) (JM216) in human ovarian carcinoma cell lines: identitication of a plasma membrane protein associated with cisplatin resistance. Clin Cancer Res 1995; 1: 981-9
12. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993; 67: 1171-6
13. Mistry P, Kelland LR, Abel G, et al. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 1991; 64: 215-20
14. Koberle B, Masters JRW, Hartley JA, et al. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999; 9: 273-6
15. Dabholkar M, Vionnet J, Bostick-Bruton F, et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994; 94: 703-8
16. Brown R, Hirst GL, Gallagher WM, et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997; 15: 45-52
17. Vaisman A, Varchenko M, Umar A, et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998; 58: 3579-85
18. Branch P, Masson M, Aquilina G, et al. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene 2000; 19: 3138-45
19. Kelley SL, Basu A, Teicher BA, et al. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988 241: 1813-1815
20. Reed E, Yuspa SH, Zwelling LA, et al. Quantitation of cis-diammine-dichloroplatinum II (cisplatin)-DNA intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest 1986 77: 545-50
21. Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000; 59: 9-17
22. du Bois A. Treatment of advanced ovarian cancer. Eur J Cancer 2001; 37: S1-7
23. Adams M, Calvert AH, Carmichael J, et al. Chemotherapy for ovarian cancer: a consensus statement on standard practice. Br J Cancer 1998; 78: 1404-6
24. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6
25. Piccart MJ, Lamb H, Vermorken JB. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol 2001; 12: 1195-203
26. Burchenal JH, Kalaher K, Dew K, et al. Rationale for development of platinum analogs. Cancer Treat Rep 1979 63: 1493-8
27. Kelland LR, Jones M, Abel G, et al. Human ovarian carcinoma cell lines and companion xenografts: a disease oriented approach to new platinum anticancer drug development. Cancer Chemother Pharmacol 1992; 30: 43-50
28. O'Rourke TJ, Weiss GR, New P, et al. Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812). Anticancer Drugs 1994; 5: 520-6
29. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in cell lines of the National Cancer Institute's Anticancer drug screen panel. Biochem Pharmacol 1996; 52: 1855-65
30. Armand J-P, Boige V, Raymond E, et al. Oxaliplatin in colorectal cancer: an overview. Semin Oncol 2000; 27: 96-104
31. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95-8
32. Piccart MJ, Green JA, Lacave AJ, et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized Phase II of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 2000; 18: 1193-202
33. Kishimoto S, Noguchi T, Yamaoka T, et al. Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration. Biol Pharm Bull 2000; 23: 344-8
34. Kelland LR, Abel G, McKeage MJ, et al. Preclinical antitumor evaluation of Bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res 1993; 53: 2581-6
35. McKeage MJ, Raynaud F, Ward J, et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 1997; 15: 2691-700
36. Kelland LR. An update on satraplatin: the first orally available platinum anticancer drug. Expert Opin Investig Drugs 2000; 9: 1373-82
37. Peereboom D, Wood L, Connell C, et al. Phase II trial of oral platinum (JM-216) in hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 1998; 439: 1210
38. Holford J, Raynaud FI, Murrer BA, et al. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473). Anticancer Drug Des 1998; 13: 1-18
39. Holford J, Sharp SY, Murrer BA, et al. In vitro circumvention of cisplatin-resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 1998; 77: 366-73
40. Raynaud FI, Boxall FE, Goddard PM, et al. Cis-amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology and pharmacokinetics in mice. Clin Cancer Res 1997; 3: 2063-74
41. Kelland L, Judson I, Koehler M, et al. Preclinical and clinical overview of the novel platinum complex, ZD0473 (cis-amminedichloro[2-methylpyridine] platinum (II) [abstract no. 227]. Lung Cancer 2000; 29: 70
42. Treat J, Huang C, Damjanov N, et al. ZD0473 phase II monotherapy trial in second-line non-small cell lung cancer. European Conference of Clinical Oncology; 2001 Oct 21-25; Lisbon, A209
43. Tyrrell C, Bullard S, Barber J, et al. Open-label phase II study of ZD0473 in patients with metastatic hormone-refractory prostate cancer. European Conference of Clinical Oncology; 2001 Oct 21-25; Lisbon, A209
44. Schiller J, Bonomi P, Modiano M, et al. Activity of ZD0473 in small-cell lung cancer: an update in patients relapsing after one prior chemotherapy regimen. European Conference of Clinical Oncology; 2001 Oct 21-25; Lisbon 2001, A219
45. Gore M, Atkinson RJ, Dirix L, et al. ZD0473 Phase II monotherapy trial in second-line ovarian cancer. European Conference of Clinical Oncology; 2001 Oct 21-25; Lisbon 2001, A967
46. Brabec V, Kasparkova J, Vrana O, et al. DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent. Biochemistry 1999; 38: 6781-90
47. Pratesi G, Perego P, Polizzi D, et al. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Br J Cancer 1999; 80: 1912-9
48. Manzotti C, Pratesi G, Menta E, et al. BBR3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin Cancer Res 2000; 6: 2626-34
49. Sharp SY, Kelland LR. BBR-3464. Curr Opin Oncologic Endocr Metab Invest Drugs 2000; 2: 353-60
50. Sessa C, Capri G, Gianni L, et al. Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. Ann Oncol 2000; 11: 977-83
51. Calvert AH, Thomas H, Colombo N, et al. Phase II clinical study of BBR3464, bifunctional platinum analogue, in patients with advanced ovarian cancer. European Conference of Clinical Oncology; 2001 Oct 21-25; Lisbon 2001, A965
52. Scagliotti G, Crino L, De Marinis F, et al. Phase II trial of BBR3464, a novel, bifunctional platinum analog, in advanced but favorable outcome, non small cell lung cancer patients. European Conference of Clinical Oncology; 2001 Oct 21-25; Lisbon 2001, A182
53. McKeage MJ. Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs 2001; 10: 1-10
54. Gietema JA, Veldhuis G-J, Guchelaar H-J, et al. Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. Br J Cancer 1995; 71: 1302-7
55. Kavanagh JJ, Edwards CL, Freedman RS, et al. A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer. Gynecol Oncol 1995; 58: 106-9
56. Kim NK, Im S-A, Kim D-W, et al. Phase II clinical trial of SK-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. Cancer 1999; 86: 1109-15
57. Akaza H, Togashi M, Nishio Y, et al. Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. Cancer Chemother Pharmacol 1992; 31: 187-92
58. Amtmann E, Zoller M, Wesch H, et al. Antitumoral activity of a sulphur-containing platinum complex with an acidic pH optimum. Cancer Chemother Pharmacol 2001; 47: 461-6